Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

Liu Y, Malin JL, Diamant AL, Thind A, Maly RC.

Breast Cancer Res Treat. 2013 Feb;137(3):829-36. doi: 10.1007/s10549-012-2387-8. Epub 2012 Dec 23.

2.

Breast reconstructive surgery in medically underserved women with breast cancer: the role of patient-physician communication.

Maly RC, Liu Y, Kwong E, Thind A, Diamant AL.

Cancer. 2009 Oct 15;115(20):4819-27. doi: 10.1002/cncr.24510.

3.

Treatment-related symptoms among underserved women with breast cancer: the impact of physician-patient communication.

Maly RC, Liu Y, Leake B, Thind A, Diamant AL.

Breast Cancer Res Treat. 2010 Feb;119(3):707-16. doi: 10.1007/s10549-009-0418-x. Epub 2009 May 16.

4.

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI.

J Clin Oncol. 2010 Sep 20;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655. Epub 2010 Jun 28.

5.

Quality of life over 5 years after a breast cancer diagnosis among low-income women: effects of race/ethnicity and patient-physician communication.

Maly RC, Liu Y, Liang LJ, Ganz PA.

Cancer. 2015 Mar 15;121(6):916-26. doi: 10.1002/cncr.29150. Epub 2014 Nov 19.

6.

Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.

Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G.

Am J Clin Oncol. 2013 Apr;36(2):181-7. doi: 10.1097/COC.0b013e3182436ec1.

7.

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P.

Ann Oncol. 2009 Mar;20(3):431-6. doi: 10.1093/annonc/mdn646. Epub 2009 Jan 15.

8.

Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.

Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, O'Regan R.

Patient Educ Couns. 2014 Apr;95(1):98-103. doi: 10.1016/j.pec.2013.12.019. Epub 2014 Jan 10.

PMID:
24492157
9.

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R.

J Clin Oncol. 2009 Jul 20;27(21):3445-51. doi: 10.1200/JCO.2008.19.2419. Epub 2009 May 18.

10.

Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer.

Liu Y, Diamant AL, Thind A, Maly RC.

Breast Cancer Res Treat. 2010 Feb;119(3):745-51. doi: 10.1007/s10549-009-0447-5. Epub 2009 Jun 24.

11.

Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ.

Eur J Cancer. 2015 Sep;51(14):1890-6. doi: 10.1016/j.ejca.2015.06.113. Epub 2015 Jul 10.

PMID:
26169018
12.

Provider communication effects medication adherence in hypertensive African Americans.

Schoenthaler A, Chaplin WF, Allegrante JP, Fernandez S, Diaz-Gloster M, Tobin JN, Ogedegbe G.

Patient Educ Couns. 2009 May;75(2):185-91. doi: 10.1016/j.pec.2008.09.018. Epub 2008 Nov 14.

13.

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Kimmick G, Edmond SN, Bosworth HB, Peppercorn J, Marcom PK, Blackwell K, Keefe FJ, Shelby RA.

Breast. 2015 Oct;24(5):630-6. doi: 10.1016/j.breast.2015.06.010. Epub 2015 Jul 16.

PMID:
26189978
14.

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, Segui MA, MargelĂ­ M, Arcusa A, Prat A, Garcia M, Borras JM.

Br J Cancer. 2012 Oct 9;107(8):1249-56. doi: 10.1038/bjc.2012.389. Epub 2012 Sep 6.

15.

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M.

Breast Cancer Res Treat. 2012 May;133(1):367-73. doi: 10.1007/s10549-012-1961-4.

PMID:
22286315
16.

Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time.

Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R.

Ann Oncol. 2012 Apr;23(4):882-90. doi: 10.1093/annonc/mdr330. Epub 2011 Jul 25.

17.

The impact of primary care physicians on follow-up care of underserved breast cancer survivors.

Maly RC, Liu Y, Diamant AL, Thind A.

J Am Board Fam Med. 2013 Nov-Dec;26(6):628-36. doi: 10.3122/jabfm.2013.06.120345.

18.

Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.

Sedjo RL, Devine S.

Breast Cancer Res Treat. 2011 Jan;125(1):191-200. doi: 10.1007/s10549-010-0952-6. Epub 2010 May 22.

PMID:
20495864
19.

What influences diagnostic delay in low-income women with breast cancer?

Maly RC, Leake B, Mojica CM, Liu Y, Diamant AL, Thind A.

J Womens Health (Larchmt). 2011 Jul;20(7):1017-23. doi: 10.1089/jwh.2010.2105. Epub 2011 Apr 12.

20.

Adherence to hormone therapy among women with breast cancer.

Brito C, Portela MC, de Vasconcellos MT.

BMC Cancer. 2014 Jun 3;14:397. doi: 10.1186/1471-2407-14-397.

Items per page

Supplemental Content

Write to the Help Desk